Abstract 1096
Background
OncotypeDX (ODX®) can enhance prediction of breast cancer recurrence, guiding adjuvant treatment options. However, the opportunity to access this test is not always possible. The aim of this study is to investigate the correlation between phenotypical tumor characteristics, quantitative classical immunohistochemistry (IHC) and recurrent score (RS) resulting from ODX®.
Methods
All breast cancer patients who underwent ODX® between 2014 and 2018 were retrospectively included in the study. The data selected for analysis were age, menopausal status, pathological and IHC features. IHC was performed with standardized quantitative methods. Dataset was split into two subsets (70% for training and 30% for internal validation). Logistic models were built with statistically significant features for predicting RS ≤ 25 or ≤ 20. An external validation set, provided by another center, was used to test reliability of prediction models.
Results
The internal dataset included 407 patients (Table) who underwent ODX®. Mean age was 53.7 (31-80) and 222 patients (54.55%) were > 50 years old. ODX® results showed: 67 patients (16.6%) between 0-10, 272 patients between 11-25 (66.8%) and 68 pts > 26 (16.6%). At the logistic regression analysis, RS score was significantly associated with ER (p = 0.004), PgR (p < 0.001), and Ki67% (p < 0.001) with the threshold equal to 25. Above patients with RS ≤ 25, the generalized linear regression resulted in a well calibrated model with an AUC of 92.2% (sensitivity 84.2%; specificity 80.1%). External validation set included 180 patients and confirmed the model performance with an AUC of 82.3% and good calibration. A nomogram predicting RS score ≤25 was generated.Table:
261P Tumor characteristics training set + internal test set
Training + internal test set – Tumor characteristics | ||
---|---|---|
Histological subtype classification | Invasive Ductal Carcinoma | 318 pts (78,1%) |
Invasive Lobular Carcinoma | 47 pts (11,5%) | |
Other | 42 pts (10,3%) | |
Grading | 1 | 28 pts (6.8%) |
2 | 268 pts (65,8%) | |
3 | 111 pts (27,3%) | |
pT | 1a | 3 pts (0,7%) |
1b | 38 pts (9,3%) | |
1c | 216 pts (53,1%) | |
2 | 143 pts (35,1%) | |
3 | 6 pts (1,5%) | |
4 | 1 pt (0,3%) | |
pN | 0 | 233 pts (57,2%) |
0i+ | 12 pts (3%) | |
1mic | 43 pts (10,6%) | |
1 | 108 pts (26,5%) | |
NA | 11 pts (2,7%) | |
Mean T diameter [cm] | 1.9 (Range 0,2-8,5) | |
Mean Sentinel Lymph Node (SLN) diameter [mm] | 1.7 (Range 0-40) | |
Mean Axillary Lymph Node (ALN) diameter [mm] | 0.8 (Range 0-25) | |
Mean N Ratio | 0.14 (0.00 – 1.00) | |
SLN involvement [n° of nodes] | 0 | 261 pts (64,1%) |
1 | 112 pts (27,5%) | |
2 | 24 pts (5,8%) | |
3 | 1 pt (0,2%) | |
NA | 9 pts (2,2%) | |
ALN involvement [n° of nodes] | 0 | 338 pts (83%) |
0i+ | 4 pts (1%) | |
1mic | 3 pts (0,7%) | |
1 | 31 pts (7,6%) | |
2 | 8 pts (2%) | |
3 | 5 pts (1,2%) | |
5 | 1 pt (0,2%) | |
NA | 17 pts (4,1%) | |
Multifocality | Yes | 97 pts (23,8%) |
No | 300 pts (73,7%) | |
NA | 10 pts (2.5%) | |
Multicentricity | Yes | 20 pts (4,9%) |
No | 376 pts (92,4%) | |
NA | 11 pts (2,7%) | |
PVI | Absent | 242 pts (59,4%) |
Focal | 51 pts (12,5%) | |
Moderate | 32 pts (7,8%) | |
Massive | 59 pts (14,5%) | |
NA | 23 pts (5,6%) | |
Mean ER expression | 87,9% (Range 1-100) | |
Mean PgR expression | 62.2% (Range 0-100) | |
Mean AR expression | 7.7% (Range 0-90) | |
Mean Ki67% expression | 29.8% (Range 0-90) | |
Her2 Expression | 0 | 187 pts (46%) |
1 | 112 pts (27,5%) | |
2 | 104 pts (25,5%) | |
NA | 4 pts (0,9%) | |
Fluorescence in situ hybridization (FISH) for HER-2 | Not determined | 300 pts (73,7%) |
Not amplificated | 100 pts (23,7%) | |
Undetermined | 1 pt (0,2%) | |
Equivocal | 1 pt (0,2%) |
Conclusions
Quantitative IHC presents a good correlation with RS score in patients with RS ≤ 25, also in external validation set. A nomogram for physician that enhances a cost/effectiveness clinical approach practice has been developed. Prospective clinical application will be tested in further studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fabio Marazzi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4546 - Efficacy and toxicity of weekly carboplatin and paclitaxel as induction or palliative treatment in advanced esophageal cancer patients
Presenter: Femke de Man
Session: Poster Display session 2
Resources:
Abstract
5908 - Perioperative chemotherapy with Docetaxel, Oxaliplatin, Fluorouracil and Leucovorin (FLOT) versus Epirubicin, Platinum and Capecitabine or Flourouracil (EOX/ECF) in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma- Safety and response data from India.
Presenter: Tanuj Chawla
Session: Poster Display session 2
Resources:
Abstract
937 - Phase II Study of Preoperative Radiotherapy Combined with S-1 plus Cisplatin in Clinically Resectable Type 4 or Large Type 3 Gastric Cancer: OGSG1205
Presenter: Shunji Endo
Session: Poster Display session 2
Resources:
Abstract
1119 - Observational Study of the Peritoneal Washing Cytology Positive Gastric Cancer without Gross Peritoneal Metastasis Underwent Radical D2 Gastrectomy.
Presenter: Jun Eul Hwang
Session: Poster Display session 2
Resources:
Abstract
3744 - Primary results of multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII)
Presenter: Akira Miki
Session: Poster Display session 2
Resources:
Abstract
5091 - Multicenter Phase I/II Feasibility Study of Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction (GMBH-STO-0114)
Presenter: Kathrin Heinrich
Session: Poster Display session 2
Resources:
Abstract
2891 - A phase I study of Docetaxel/Oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction
Presenter: Kei Hosoda
Session: Poster Display session 2
Resources:
Abstract
2994 - Apatinib combined with docetaxel in second-line treatment of advanced gastric cancer: a prospective clinical study (Data updated)
Presenter: Mudan Yang
Session: Poster Display session 2
Resources:
Abstract
3000 - A multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604)
Presenter: Daisuke Takahari
Session: Poster Display session 2
Resources:
Abstract
4653 - Impact of Pembrolizumab (pembro) Versus Paclitaxel on Health-Related Quality of Life (HRQoL) in Patients With Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer That Has Progressed After First-Line Chemotherapy (KEYNOTE-061)
Presenter: Eric Van Cutsem
Session: Poster Display session 2
Resources:
Abstract